A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs XmAb-18087 (Primary)
- Indications Gastrointestinal stromal tumours; Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Xencor
- 27 Feb 2018 According to a Xencor media release, initial data from this study is expected in 2019.
- 22 Feb 2018 According to a Xencor media release, the first patient has been dosed in this trial.
- 19 Jan 2018 Status changed from planning to recruiting.